The US FDA has issued new guidance on ways to expand development of non-opioid treatment options for chronic pain.

Journavx (suzetrigine) 50 mg oral tablets, the first-in-class non-opioid analgesic for moderate to severe acute pain, was ...

The agency says it’s open to offering speedy approval pathways for new pain medications that can fight the ongoing opioid ...

By Stephanie Brown HealthDay ReporterWEDNESDAY, Sept. 10, 2025 (HealthDay News) -- The U.S. Food and Drug Administration ...

Manufacturers shouldn't try to address this guidance without specific feedback and support from cybersecurity experts.c ...

U.S. Food and Drug Administration Commissioner Martin Makary said on Friday that Hims & Hers' Super Bowl advertisement ...

Advisory committee meetings help FDA scientists make decisions and increase public understanding of drug regulation, and ...

The U.S. Food and Drug Administration will send out around 100 cease-and-desist enforcement notices and thousands of letters ...

In today's Morning Rounds newsletter, NIH is finally spending down its coffers, FDA eyes tighter regulations on chatbots for ...

Sentara Health said it "missed the mark" on its initial COVID-19 vaccine guidance due to changes in FDA guidance and the gap ...